| | Power your data-science drug discovery Introducing the QIAGEN Biomedical Knowledge Base. The first expertly curated knowledge base that comes from high-quality manually curated content with granularity and causality that spans multiple domains. Learn more |
AstraZeneca will have to wait a little longer for fruit from $3.5B Ionis ATTR partnership Pfizer loses top vaccine scientist Jansen who led drive for COVID-19 shot, searches for successor Celltrion tacks on a third Class I recall for unauthorized use of rapid COVID tests OIG dings Medicare Advantage plans for use of prior authorization As superstar Revlimid fades faster than expected, BMS trims $600M from its 2022 sales projection Human testing for Praxis' lead epilepsy drug held up after FDA clinical hold ResMed shaves $100M off earnings expected from Philips’ ventilator recall Amid legal tumult, J&J shareholders reject proposal to end talc sales worldwide Walmart Health rolls out virtual diabetes program as retail giant moves deeper into treating chronic conditions AbbVie's cystic fibrosis long-game doesn't pay off, as Galapagos med fails in triple combo Novo's Wegovy supply rebound on track for later this year as demand stays strong Ex-Cerebral executive files lawsuit claiming the startup overprescribed ADHD meds Sanofi moves patients out of Ukraine warzone in 'Herculean effort' to preserve MS trials Dexcom keeps up the pace as it plots international continuous glucose monitor launches Rest easy—research shows gene editing could hold the key to deep sleep Featured Story | By Annalee Armstrong AstraZeneca is going to have to wait a little bit longer to see the fruits of its more than $3.5 billion partnership with Ionis Pharmaceuticals. The deal is the Big Pharma’s attempt to crack into a rapidly changing and competitive market for a rare heart disease. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky Amid Pfizer's run as a global vaccine heavyweight—emphasized lately by its success with COVID-19 shot Comirnaty—the company is losing a top scentist. read more By Andrea Park Three is turning out to be a not-so-magical number for Celltrion, which this week racked up a third Class I tag in less than two months for yet another recall of its rapid antigen COVID-19 tests. read more By Paige Minemyer Medicare Advantage plans' use of prior authorization is raising some eyebrows at the Office of Inspector General. read more By Kevin Dunleavy Shortly after announcing that the FDA had approved its potential blockbuster Camzyos, Bristol Myers Squibb also brought negative news about cancer powerhouse Revlimid. Now challenged by generic competition, sales of Revlimid came in below expectations at $2.8 billion in the first quarter, prompting BMS to slice $500 million off its 2022 projection for the med. read more By Gabrielle Masson The FDA has slapped a clinical hold on Praxis Precision Medicines’ PRAX-222, a drug aimed at treating early-onset epilepsy and one of biotech’s three product candidates set to enter clinical-stage development by the end of this year. read more By Andrea Park With chip shortages still ballooning around the world, ResMed has been forced to deflate its expectations for what it hoped to reap in the vacuum left by Philips’ major ventilator recall. read more By Kevin Dunleavy Johnson & Johnson will continue to sell its talc products in many markets around the world after resisting a proposal to discontinue the practice. At J&J’s annual meeting on Thursday, a proposal failed to receive the majority needed to discontinue sales of the products that plaintiffs claim cause cancer. read more By Heather Landi Walmart's telehealth provider, MeMD, is rolling out the virtual diabetes program as a standalone service or as part of a comprehensive medical and behavioral telehealth program for enterprise customers and health plans. read more By Annalee Armstrong AbbVie is discontinuing a cystic fibrosis medicine after an interim analysis revealed that the therapy did nothing when added to a triple-combo regimen, putting a dent in the pharma’s efforts to compete with Vertex’s Trikafta. read more By Fraiser Kansteiner As a potential Eli Lilly rival looms, Novo Nordisk’s obesity newcomer Wegovy is gearing up for a supply rebound in the back half of the year, executives said Friday. Meanwhile, Novo for the first time broke out sales figures for the med, which analysts predict could eventually reach blockbuster heights. read more By Heather Landi A former executive at Cerebral, a well-funded online mental health startup, claims in a labor lawsuit that the company fired him after he complained about unlawful business practices. read more By James Waldron Sanofi has moved clinical trial patients out of Ukraine, as European pharma companies scramble to maintain their multiple sclerosis studies in the wake of the conflict brought on by the Russian invasion. read more By Conor Hale The diabetes sensor company posted a 25% increase in sales for the first three months of this year compared to the same period in 2021. read more By James Waldron A good night’s rest can often be the best medicine, which means new research into gene editing that may have unlocked the part of brain responsible for deep sleep could lead to exciting new therapy options. read more |
